Eur Urol

• 

  Publication Venue For

  • Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]..  82:e18-e19. 2022
  • Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021..  82:115-141. 2022
  • What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021..  82:6-11. 2022
  • Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy..  81:446-455. 2022
  • Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial..  81:223-228. 2022
  • Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?.  79:663-664. 2021
  • Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis..  79:419-426. 2021
  • Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer..  79:353-361. 2021
  • Antibiotics and Immunotherapy: Too Much of Anything is Bad!.  78:544-545. 2020
  • Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study..  78:603-614. 2020
  • En Bloc Resection of Bladder Tumors: Style or Substance?.  78:570-571. 2020
  • National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results..  78:531-532. 2020
  • A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry..  78:316-320. 2020
  • Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial..  78:347-357. 2020
  • From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guérin Trials in Non-muscle-invasive Bladder Cancer..  78:400-401. 2020
  • Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus..  78:371-378. 2020
  • A Comparison of Perioperative Outcomes Between Single-port and Multiport Robot-assisted Laparoscopic Prostatectomy..  77:671-674. 2020
  • Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83..  77:129-130. 2020
  • Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?.  76:740-742. 2019
  • Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer..  76:562-571. 2019
  • RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression..  76:157-166. 2019
  • Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes..  74:720-721. 2018
  • Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma..  74:842-843. 2018
  • Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients..  74:537-539. 2018
  • Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer..  74:526. 2018
  • Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy..  74:234-235. 2018
  • Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer..  74:99-106. 2018
  • Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial..  74:66-73. 2018
  • Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression..  73:322-339. 2018
  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017..  73:178-211. 2018
  • Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results..  73:62-68. 2018
  • Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review..  73:40-50. 2018
  • RECISTing the Temptation to Prematurely Stop Nivolumab..  72:377-378. 2017
  • Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors..  72:4-6. 2017
  • Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death..  71:740-747. 2017
  • Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer..  71:168-171. 2017
  • Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma..  71:79-80. 2017
  • New and Established Technology in Focal Ablation of the Prostate: A Systematic Review..  71:17-34. 2017
  • Improved Reporting of Randomized Controlled Trials in the Urologic Literature..  70:1044-1049. 2016
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort..  70:963-970. 2016
  • Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer..  70:714-717. 2016
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer..  70:675-683. 2016
  • Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer..  70:211-213. 2016
  • Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis..  70:209-210. 2016
  • Percutaneous Nephrolithotomy: Update, Trends, and Future Directions..  70:382-396. 2016
  • Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel..  69:980-983. 2016
  • Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?.  69:231-244. 2016
  • Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results..  69:116-128. 2016
  • Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach..  68:891-898. 2015
  • Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?.  68:40-41. 2015
  • Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas..  68:77-83. 2015
  • Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting..  67:771-777. 2015
  • Burden of disease matters when it comes to systemic therapy for prostate cancer..  67:448-450. 2015
  • Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology..  67:569-576. 2015
  • Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort..  67:310-318. 2015
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?.  67:210-211. 2015
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer..  67:100-110. 2015
  • Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity..  67:85-97. 2015
  • Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer..  65:852-855. 2014
  • Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?.  65:873-874. 2014
  • Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen..  65:809-815. 2014
  • New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?.  65:300-302. 2014
  • The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer..  65:3-6. 2014
  • Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility..  64:394-396. 2013
  • Novel immunotherapeutic strategies in development for renal cell carcinoma..  63:881-889. 2013
  • New and emerging therapies for bone metastases in genitourinary cancers..  63:309-320. 2013
  • Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?.  63:210-211. 2013
  • ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings..  63:58-66. 2013
  • Rationale for percutaneous biopsy and histologic characterisation of renal tumours..  62:491-504. 2012
  • Objective evaluation of bone metastases in prostate cancer: to what end?.  62:85-87. 2012
  • Prevalence of kidney stones in the United States..  62:160-165. 2012
  • A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes..  61:664-675. 2012
  • Contemporary management of ureteral stones..  61:764-772. 2012
  • Vesicoureteral reflux: current trends in diagnosis, screening, and treatment..  61:773-782. 2012
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer..  61:549-559. 2012
  • Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy..  61:443-451. 2012
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer..  61:363-369. 2012
  • Baseline prostate-specific antigen testing at a young age..  61:1-7. 2012
  • Treatment of localised renal cell carcinoma..  60:662-672. 2011
  • The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review..  60:81-93. 2011
  • Contemporary management of postprostatectomy incontinence..  59:985-996. 2011
  • Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center..  58:142-147. 2010
  • Focal therapy for prostate cancer: possibilities and limitations..  58:57-64. 2010
  • Predicting occult multifocality of renal cell carcinoma..  58:118-126. 2010
  • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics..  57:836-842. 2010
  • Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer..  57:727-728. 2010
  • Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer..  68:937-938. 2015
  • Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer..  66:390-391. 2014
  • Maintenance bacillus Calmette-Guérin: why is there continued debate?.  64:586-587. 2013
  • Interpreting a study on bladder cancer screening..  64:48-50. 2013
  • Words of wisdom. Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance..  64:171-172. 2013
  • When should we pull the trigger for post-radical prostatectomy radiotherapy?.  62:488-490. 2012
  • Open versus laparoscopic nephroureterectomy: is there really a debate?.  61:722-723. 2012
  • Is tumor response important for renal carcinoma?.  59:16-17. 2011
  • Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]..  58:644. 2010
  • Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts..  57:452. 2010
  • Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example..  55:1266-1268. 2009
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 2020
  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. 2017